Missouri City, TX, United States of America

Kyle R Covington

This inventor holds 2 USPTO granted patents and 8 published patent applications and 2 EPO patents. Top assignee: Castle Biosciences, Incorporated. Active years: 2024.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Kyle R Covington in Cancer Treatment

Introduction

Kyle R Covington is an accomplished inventor based in Missouri City, TX (US). He has made significant contributions to the field of oncology, particularly in the diagnosis and treatment of cutaneous squamous cell carcinoma (cSCC). With a total of two patents to his name, Covington's work is paving the way for advancements in cancer care.

Latest Patents

Covington's latest patents focus on methods for diagnosing and treating patients with cutaneous squamous cell carcinoma. The present disclosures relate to innovative methods for predicting the risk of recurrence and/or metastasis in primary cSCC. These advancements are crucial for improving patient outcomes and tailoring treatment plans.

Career Highlights

Kyle R Covington is currently associated with Castle Biosciences, Incorporated, where he continues to develop groundbreaking solutions in cancer diagnostics. His expertise and dedication to research have positioned him as a key figure in the medical community.

Collaborations

Covington collaborates with notable professionals in his field, including Robert Willis Cook and Derek Maetzold. These partnerships enhance the research and development efforts at Castle Biosciences, contributing to the overall mission of improving cancer treatment.

Conclusion

Kyle R Covington's innovative work in the field of oncology exemplifies the impact of dedicated inventors on healthcare. His patents and collaborations are instrumental in advancing the diagnosis and treatment of cutaneous squamous cell carcinoma.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…